Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Inclusion criteria: * Age ≥18-80 old, male or female * African Americans * Willing to give written informed consent and to comply with study visits and restrictions, including being able to speak, write and understand English * Pt who have received a primary or secondary transplant * Pt least 6 (six) mth post-transplant and on a stable dose of tacrolimus * BMI ≥19 * Pt who are sero-positive for Hepatitis B or C positive may also be enrolled * Pt maintained on concurrent immunosuppression with stable doses during screening * Pt on a proton PPI remain on the same PPI formulation and dose during the PK portion of the study. * During PK phase Only: Pt taking any medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food supplements (including grapefruit, and pomegranate products), or medications must continue the same dose and are willing to continue the same dose/routine * During PK phase Only: the patient is not scheduled to begin any new medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food Exclusion Criteria: * Evidence of acute rejection episode within the past three months * Pt not Africa-American * Recipients of organ transplants other than kidney * Known to be HIV positive at transplant * Pt with recurrent focal segmental glomerulosclerosis (FSGS) * Pt with any severe medical condition (including infection) requiring acute or chronic treatment * Pt with a positive DSA * Pt with a positive BK virus results * GFR \< 25 ml/min measured by MDRD4 as SOC within last 30 days * Patients with AST, ALT, total bilirubin \> 2.5 x ULN or evidence of severe liver disease * Pt with WBC \< to 2000/mm3 or ANC \< to 1500 mm3 with PLT \< 75,000/mm3 or HGB \< 8 g/dl * Pt with mental or physical conditions or known non-adherence * Presence of intractable immunosuppressant complications of side effects resulting in dose adjustment of tacrolimus * Exposed to investigational therapy within 30 days prior to enrollment * No anticipated changes in the immunosuppressive regimen, other than those specified by the study protocol * Pt with severe diabetic gastroparesis or other severe GI disturbances * Pt who have underwent gastric banding or gastric bypass at any time pre or post-transplant * Pregnant or nursing (lactating) women, or planning to become pregnant * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC of method